माधवी नेत्रालय संस्थान

अनुसंधान और नवाचार

हमारे परामर्शदाताओं द्वारा प्रकाशित सहकर्मी-समीक्षित नेत्र विज्ञान शोध — रेटिना चिकित्सा, बायोसिमिलर और एंटी-VEGF देखभाल को आरा, बिहार की क्लिनिकल प्रैक्टिस से जोड़ता है।

39DOI प्रकाशन
2022–2026प्रकाशन वर्ष
रेटिनामुख्य फोकस

माधवी नेत्रालय एक तृतीयक नेत्र अस्पताल है — और एक संस्थान भी, जहाँ अनुसंधान रोगी देखभाल का हिस्सा माना जाता है। हमारे परामर्शदाता Eye, Ophthalmology, JAMA Ophthalmology और अन्य अंतरराष्ट्रीय पत्रिकाओं में प्रकाशित करते हैं, और बायोसिमिलर, फैरिसिमैब तथा वास्तविक-दुनिया एंटी-VEGF अभ्यास पर राष्ट्रीय व अंतरराष्ट्रीय सहयोग करते हैं।

नीचे हमारा DOI प्रकाशन सूची है। प्रत्येक प्रविष्टि मूल शोध-पत्र के DOI लिंक पर जाती है। संस्थान संबद्धता वाली लाइव PubMed सूची के लिए पृष्ठ के अंत में PubMed लिंक देखें।

प्रकाशित DOI सूची

39 सहकर्मी-समीक्षित प्रकाशन — नवीनतम पहले।

  1. FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings – FORCE study

    Sharma A., Nicholson L., Vazquez-Alfageme C., Sivagnanavel V., Fausto R., Soare M., et al.

    2025 · Eyedoi:10.1038/s41433-025-04030-7

  2. Aflibercept 2 mg biosimilar (Tyalia) - real-world experience from IRAN (ATRIA study)

    Avadzadeh S., Sharma A., Parvaresh M., Ghasemi Falavarjani K., , Kuppermann B., et al.

    2025 · Eyedoi:10.1038/s41433-025-03813-2

  3. Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study)

    Ueda-Consolvo T., Ishida M., Nakamura T., Yanagisawa S., Tsuboi K., Wakabayashi T., et al.

    2024 · Eyedoi:10.1038/s41433-024-03220-z

  4. Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study

    Sharma A., Holz F., Kumar N., Sarraf D., Ayachit S., Mishra C., et al.

    2025 · Journal of VitreoRetinal Diseasesdoi:10.1177/24741264251322213

  5. Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally

    Sharma A., Woo S., Lee C., Kumar N., Parachuri N., Bandello F., et al.

    2025 · Eyedoi:10.1038/s41433-025-03732-2

  6. Global experience of faricimab in clinical settings - a review

    Sharma A., Kumar N., Parachuri N., Loewenstein A., Bandello F., Kuppermann B.

    2024 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2024.2336087

  7. Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs

    Sharma A., Kumar N., Parachuri N., Bandello F., Loewenstein A., Kuppermann B.

    2024 · Eyedoi:10.1038/s41433-024-03001-8

  8. Knowledge, attitude, and practice patterns of Indian ophthalmologists regarding medicolegal issues

    Agrawal D., Heda A., Ghosh S., Kalia S., Bhatia K., Kumar N., et al.

    2023 · Indian Journal of Ophthalmologydoi:10.4103/IJO.IJO_1084_23

  9. Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases

    Sharma A., Loewenstein A., Parachuri N., Kumar N., Kuppermann B.

    2023 · Journal of VitreoRetinal Diseasesdoi:10.1177/24741264231202080

  10. Aflibercept biosimilars – update on the development progress

    Sharma A., Loewenstein A., Kumar N., Parachuri N., Bandello F., Kuppermann B.

    2024 · Eyedoi:10.1038/s41433-023-02813-4

  11. Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge–

    Sharma A., Loewenstein A., Parachuri N., Kumar N., Rasal A., Bandello F., et al.

    2024 · Eyedoi:10.1038/s41433-023-02698-3

  12. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia

    Sharma A., Kumar N., Parachuri N., Loewenstein A., Bandello F., Kuppermann B.

    2023 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2023.2239706

  13. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)

    Sharma A., Holz F., Regillo C., Freund K., Sarraf D., Khanani A., et al.

    2023 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2023.2176218

  14. Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists

    Sharma A., Khanani A., Parachuri N., Kumar N., Bandello F., Kuppermann B.

    2023 · International Journal of Retina and Vitreousdoi:10.1186/s40942-023-00446-z

  15. Immunogenicity: Clouding the Future of Intravitreal Therapy

    Sharma A., Kumar N., Parachuri N., Bandello F., Kuppermann B.

    2023 · Ocular Immunology and Inflammationdoi:10.1080/09273948.2022.2139273

  16. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians–

    Sharma A., Kumar N., Parachuri N., Regillo C., Bandello F., Kuppermann B.

    2023 · Eyedoi:10.1038/s41433-022-02287-w

  17. Approved biosimilar ranibizumab—a global update

    Sharma A., Kondo M., Iwahashi C., Parachuri N., Kumar N., Bandello F., et al.

    2023 · Eyedoi:10.1038/s41433-022-02246-5

  18. Biosimilar anti-VEGF—Yardsticks to ensure biosimilarity

    Sharma A., Parachuri N., Kumar N., Bandello F., Kuppermann B.

    2023 · Eyedoi:10.1038/s41433-022-02177-1

  19. Brolucizumab in polypoidal choroidal vasculopathy

    Sharma A., Parachuri N., Kumar N., Kuppermann B., Loewenstein A., Bandello F.

    2022 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2022.2094239

  20. Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in India

    Sharma A., Kumar N., Parachuri N., Kuppermann B., Bandello F.

    2022 · Indian Journal of Ophthalmologydoi:10.4103/ijo.IJO_3101_21

  21. The port delivery system with ranibizumab: understanding nuances for clinical use in the real world

    Sharma A., Parachuri N., Kumar N., Kuppermann B., Bandello F., Regillo C.

    2022 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2022.2078162

  22. Ranizurel safety evaluation in real-world -(RaSER) study

    Sharma A., Arunaprakash J., Das A., Nayaka A., Kumar N., Parachuri N., et al.

    2022 · American Journal of Ophthalmology Case Reportsdoi:10.1016/j.ajoc.2022.101358

  23. Retina: a unique subspecialty in the biosimilar landscape

    Sharma A., Kumar N., Parachuri N., Regillo C., Bandello F., Kuppermann B.

    2022 · Eyedoi:10.1038/s41433-022-01984-w

  24. On label bevacizumab for retina: where it stands

    Sharma A., Kumar N., Parachuri N., Loewenstein A., Bandello F., Kuppermann B.

    2022 · Eyedoi:10.1038/s41433-021-01909-z

  25. Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk

    Sharma A., Kumar N., Parachuri N., Sahyoun J., Kuppermann B., Bandello F.

    2022 · Expert Opinion on Biological Therapydoi:10.1080/14712598.2022.2028772

  26. Semaglutide and the risk of diabetic retinopathy—current perspective

    Sharma A., Parachuri N., Kumar N., Saboo B., Tripathi H., Kuppermann B., et al.

    2022 · Eyedoi:10.1038/s41433-021-01741-5

और देखें

PubMed पर संस्थान परिणाम देखें, शल्य चिकित्सकों से मिलें, या माधवी नेत्रालय में अपॉइंटमेंट बुक करें।